+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Healthcare Licensing with China: China - Pharmaceuticals Most Recent 100

  • ID: 5187941
  • Report
  • October 2020
  • Region: Global, China
  • 90 pages
  • Life Science Licensing
1 of 4
This trends report provides a comprehensive analysis on the most recent 100 licensing deals and negotiations reported for the Pharmaceutical companies of China from January 1, 2019 to September 30, 2020, categorized and summarized by various important aspects such as market capitalization groups, medicine groups, across key regions, licensing payment arrangements, and worldwide vs domestic licensing. Such detailed analysis helps to understand the licensing trends and directions during this time period in the Pharmaceutical sector of China. The report is extremely useful for the healthcare company executives negotiating licensing deals, as well as for the investors analyzing varied kinds of transaction options for licensing deals in the Pharmaceutical sector of China. The report provides comprehensive information with twenty one months’ healthcare licensing transactions analyzed at one place and small, medium and big multinational/non-multinational companies covered. The licensing trends and directions are summarized here after an in-depth analysis based on the comprehensive news gathering followed by insightful research.
Note: Product cover images may vary from those shown
2 of 4
Introduction

Research Design

Chapter 1: Analysis of most recent 100 healthcare inventions of China (Pharmaceuticals) licensed during last twenty one months
1.1 Market capitalization groups with most licensing deals
1.2 Medicine groups most active in licensing deals
1.3 Licensing payment arrangements most followed
1.4 Worldwide licensing vs domestic licensing

Chapter 2: Analysis of most recent 100 licensing deals of China (Pharmaceuticals) by key attributes during last twenty one months
2.1 For each of the marketcap groups
2.2 For each of the medicine groups
2.3 Across each of the regions

Chapter 3: Summary and conclusions

Appendices
Appendix 1 Most recent 100 healthcare inventions licensed for China (Pharmaceuticals) during last twenty one months - By company name
Appendix 2 List of companies/institutes covered - By company name
Appendix 3 List of companies/institutes covered - By market capitalization group and company name
Appendix 4 List of non-listed companies covered - By company name
Appendix 5 List of companies/institutes covered - By medicine group and company name
Appendix 6 List of companies/institutes covered - By terms of payment and company name
Appendix 7 Licensing deals discontinued for China (Pharmaceuticals) during last twenty one months
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

Loading
LOADING...

Adroll
adroll